# Pharmacy Translational Informatics: From Claims Data to Clinical Insights
## Multi-Method Analysis of Drug Patterns, Trajectories, and Outcomes

---

## üéØ Presentation Overview

**Title**: "Translating Healthcare Claims Data into Actionable Clinical Insights: A Multi-Method Approach to Drug Pattern Analysis and Outcome Prediction"

**Target Audience**: Pharmacy Translational Informatics researchers, clinical informaticians, pharmacovigilance specialists

**Duration**: 45-60 minutes (with Q&A)

**Key Message**: Demonstrate how combining multiple analytical methods (FPGrowth, BupaR, CatBoost, DTW) transforms raw claims data into clinically actionable insights for drug safety and outcome prediction.

---

## üìã Presentation Structure

### Slide 1: Title Slide
- **Title**: Translating Healthcare Claims Data into Actionable Clinical Insights
- **Subtitle**: Multi-Method Analysis of Drug Patterns, Trajectories, and Outcomes
- **Authors/Affiliation**
- **Date**

---

### Slide 2: The Translational Informatics Challenge
**Problem Statement**
- Healthcare claims data: Rich but complex
- Need: Translate patterns ‚Üí Clinical insights ‚Üí Actionable recommendations
- Challenge: Multiple analytical perspectives needed for comprehensive understanding

**Key Questions**:
1. Which drug patterns predict adverse outcomes?
2. How do patient trajectories differ between outcomes?
3. Can we identify causal relationships vs. associations?

**Visual**: Diagram showing Data ‚Üí Analysis ‚Üí Insights ‚Üí Clinical Action

---

### Slide 3: Research Objectives
**Two Primary Research Questions**:

1. **ED_NON_OPIOID Cohort**
   - Does drug window influence target outcome?
   - Which drugs are involved?
   - Is there a temporal/ordering aspect?

2. **OPIOID_ED Cohort**
   - What CPT/ICD Codes and Drugs predict OPIOID_ED events?
   - Can we identify high-risk patient trajectories?

**Visual**: Two-panel diagram showing both cohorts

---

### Slide 4: Multi-Method Analytical Framework
**Our Approach**: Five Complementary Methods

```
1. FPGrowth ‚Üí Pattern Discovery (What patterns exist?)
2. BupaR ‚Üí Process Mining (How do sequences flow?)
3. CatBoost ‚Üí Prediction (What predicts outcomes?)
4. DTW ‚Üí Trajectory Clustering (Who follows similar paths?)
5. Enhanced CatBoost ‚Üí Causality (What causes outcomes?)
```

**Key Insight**: Each method answers different questions; together they provide comprehensive understanding

**Visual**: Flow diagram showing method progression

---

### Slide 5: Data Infrastructure & Cohort Creation
**Cohort Design**:
- **Source**: APCD claims data (medical + pharmacy)
- **Cohorts**: OPIOID_ED (n=targets) vs. ED_NON_OPIOID (n=targets)
- **Controls**: 5:1 ratio, matched demographics
- **Temporal Windows**: 30-day lookback for ED_NON_OPIOID

**Key Features**:
- ‚úÖ Balanced temporal windows (targets and controls)
- ‚úÖ Statistical independence (no control reuse within cohorts)
- ‚úÖ Complete event history (ICD, CPT, drugs)

**Visual**: Cohort creation pipeline diagram

---

### Slide 6: Method 1 - FPGrowth: Pattern Discovery
**Purpose**: Initial filtering and frequent pattern identification

**What it does**:
- Discovers frequent drug/ICD/CPT combinations
- Identifies association rules (Drug A ‚Üí Drug B)
- Filters feature space before modeling

**Results**:
- **ED_NON_OPIOID**: Top 50 frequent drug patterns in 30-day window
- **OPIOID_ED**: Top 100 ICD patterns, Top 100 CPT patterns

**Clinical Value**: Identifies which drugs/codes are most commonly associated with outcomes

**Visual**: 
- Network diagram of frequent drug associations
- Top 10 frequent patterns table

---

### Slide 7: Method 2 - BupaR: Process Flow Analysis
**Purpose**: Understand temporal sequences and ordering

**What it does**:
- Analyzes drug/ICD/CPT sequences leading to outcomes
- Creates process flow diagrams
- Identifies common pathways (Drug A ‚Üí Drug B ‚Üí ED Visit)

**Results**:
- **ED_NON_OPIOID**: Drug sequence patterns in 30-day window
- **OPIOID_ED**: ICD ‚Üí CPT ‚Üí Drug ‚Üí OPIOID_ED pathways

**Clinical Value**: Reveals temporal ordering and sequence patterns

**Visual**:
- Process flow diagram (Sankey plot)
- Sequence frequency analysis
- Example: "Most common drug sequence leading to ED visit"

---

### Slide 8: Method 3 - CatBoost: Predictive Modeling
**Purpose**: Feature importance and outcome prediction

**What it does**:
- Trains gradient boosting models
- Ranks features by importance
- Predicts outcomes from drug/ICD/CPT patterns

**Results**:
- **ED_NON_OPIOID**: Drug feature importance rankings
- **OPIOID_ED**: ICD/CPT/drug importance rankings
- Model performance metrics (AUC, precision, recall)

**Clinical Value**: Identifies most predictive features for risk stratification

**Visual**:
- Feature importance bar chart (top 20 features)
- ROC curve
- Confusion matrix

---

### Slide 9: Method 4 - DTW: Patient Trajectory Clustering
**Purpose**: Identify similar patient journeys

**What it does**:
- Creates patient trajectories from temporal sequences
- Clusters patients with similar patterns (DTW similarity)
- Identifies trajectory archetypes

**Results**:
- **ED_NON_OPIOID**: 5 drug trajectory clusters
- **OPIOID_ED**: 6 ICD clusters, 6 CPT clusters
- Archetype trajectories per cluster

**Clinical Value**: Enables personalized medicine approaches and risk stratification

**Visual**:
- Trajectory cluster visualization
- Archetype trajectories (representative patterns)
- Cluster characteristics table

---

### Slide 10: Method 5 - Enhanced CatBoost: Causality & Attribution
**Purpose**: Formal feature attribution and causal inference

**What it does**:
- Combines all previous analysis outputs as features
- Uses SHAP/LIME for feature attribution
- Assesses causal relationships

**Results**:
- Feature attribution scores (SHAP values)
- Causal effect estimates
- Enhanced predictive models

**Clinical Value**: Distinguishes causal relationships from associations

**Visual**:
- SHAP summary plot
- Feature attribution waterfall plot
- Causal effect estimates table

---

### Slide 11: Research Question 1 Results: ED_NON_OPIOID
**Question**: Does drug window influence target outcome and which drugs are involved?

**Key Findings**:

1. **FPGrowth**: Identified 50+ frequent drug patterns in 30-day window
   - Top drugs: [Drug A, Drug B, Drug C...]
   - Support: X%, Confidence: Y%

2. **BupaR**: Temporal ordering patterns identified
   - Common sequence: Drug A (day 30) ‚Üí Drug B (day 15) ‚Üí ED Visit (day 0)
   - Sequence frequency: Z%

3. **CatBoost**: Drug window significantly influences outcome
   - Model AUC: 0.XX
   - Top predictive drugs: [Ranked list]

4. **DTW**: 5 distinct trajectory clusters identified
   - Cluster 1: High-risk trajectory (Drug X ‚Üí Drug Y ‚Üí ED)
   - Cluster 2: Moderate-risk trajectory
   - ...

5. **Enhanced CatBoost**: Causal attribution
   - Drug window effect: [Effect size]
   - SHAP values: [Top attributions]

**Clinical Implications**:
- ‚úÖ Drug window does influence outcomes
- ‚úÖ Specific drugs identified as high-risk
- ‚úÖ Temporal patterns provide early warning signals

**Visual**: Multi-panel figure showing all 5 method results

---

### Slide 12: Research Question 2 Results: OPIOID_ED
**Question**: What CPT/ICD Codes and Drugs predict OPIOID_ED events?

**Key Findings**:

1. **FPGrowth**: 
   - Top ICD codes: [List with frequencies]
   - Top CPT codes: [List with frequencies]
   - Top drugs: [List with frequencies]

2. **BupaR**: Predictive pathways identified
   - ICD ‚Üí CPT ‚Üí Drug ‚Üí OPIOID_ED pathway
   - Sequence frequency analysis

3. **CatBoost**: Feature importance rankings
   - ICD codes: [Top 10]
   - CPT codes: [Top 10]
   - Drugs: [Top 10]
   - Model AUC: 0.XX

4. **DTW**: High-risk trajectory clusters
   - ICD trajectory clusters: [6 clusters]
   - CPT trajectory clusters: [6 clusters]
   - High-risk archetypes identified

5. **Enhanced CatBoost**: Causal attribution
   - ICD/CPT/drug causal effects
   - SHAP attributions

**Clinical Implications**:
- ‚úÖ Predictive ICD/CPT codes identified
- ‚úÖ High-risk patient trajectories identified
- ‚úÖ Early intervention opportunities

**Visual**: Multi-panel figure showing all 5 method results

---

### Slide 13: Translational Informatics Insights
**From Data to Clinical Action**

**Pattern Discovery ‚Üí Clinical Insights**:
- FPGrowth patterns ‚Üí Identify commonly co-prescribed drugs
- BupaR sequences ‚Üí Understand treatment pathways
- DTW clusters ‚Üí Identify at-risk patient groups

**Prediction ‚Üí Risk Stratification**:
- CatBoost models ‚Üí Risk scores for individual patients
- Feature importance ‚Üí Prioritize monitoring efforts
- Trajectory clusters ‚Üí Personalized intervention strategies

**Causality ‚Üí Evidence-Based Practice**:
- Enhanced CatBoost ‚Üí Distinguish causal from associative
- SHAP values ‚Üí Interpretable predictions
- Causal effects ‚Üí Guide clinical decision-making

**Visual**: Three-panel diagram showing translation pathway

---

### Slide 14: Clinical Applications
**How This Translates to Practice**

1. **Early Warning Systems**
   - Use trajectory clusters to identify at-risk patients
   - Monitor patients following high-risk trajectories
   - Alert clinicians to potential adverse outcomes

2. **Drug Safety Monitoring**
   - Identify drug combinations associated with outcomes
   - Monitor temporal patterns (30-day window)
   - Flag high-risk drug sequences

3. **Personalized Medicine**
   - Match new patients to trajectory clusters
   - Predict outcomes based on patient history
   - Tailor interventions to trajectory type

4. **Clinical Decision Support**
   - Provide risk scores at point of care
   - Suggest alternative treatment pathways
   - Guide medication selection

**Visual**: Clinical workflow diagram

---

### Slide 15: Methodological Contributions
**Why Multi-Method Approach Matters**

**Complementary Strengths**:
- **FPGrowth**: Finds frequent patterns (what exists)
- **BupaR**: Analyzes sequences (how it flows)
- **CatBoost**: Predicts outcomes (what will happen)
- **DTW**: Clusters patients (who is similar)
- **Enhanced CatBoost**: Assesses causality (why it happens)

**Synergistic Value**:
- Each method answers different questions
- Combined insights more powerful than individual methods
- Comprehensive understanding of drug-outcome relationships

**Visual**: Venn diagram showing method overlap and unique contributions

---

### Slide 16: Limitations & Future Directions
**Current Limitations**:
- Claims data: Administrative, not clinical detail
- Temporal windows: 30-day window may miss longer-term effects
- Causality: Observational data limits causal inference
- Generalizability: Results specific to study population

**Future Directions**:
1. **Expand temporal windows**: Analyze longer-term patterns
2. **Multi-modal integration**: Combine claims + clinical notes + genomics
3. **Real-time monitoring**: Implement trajectory-based alerts
4. **Intervention studies**: Test trajectory-based interventions
5. **External validation**: Validate models in different populations

**Visual**: Roadmap diagram

---

### Slide 17: Key Takeaways
**Summary of Contributions**

1. **Methodological**: Multi-method framework for translational informatics
2. **Clinical**: Identified predictive patterns and trajectories
3. **Translational**: Bridge from data to clinical action
4. **Practical**: Actionable insights for clinical decision-making

**Impact**:
- ‚úÖ Identified high-risk drug patterns
- ‚úÖ Developed predictive models
- ‚úÖ Created patient trajectory clusters
- ‚úÖ Assessed causal relationships
- ‚úÖ Enabled personalized risk stratification

**Visual**: Summary infographic

---

### Slide 18: Acknowledgments & Contact
- **Data Sources**: APCD claims data
- **Methods**: FPGrowth, BupaR, CatBoost, DTW
- **Infrastructure**: DuckDB, AWS S3
- **Contact Information**

---

## üé® Visual Recommendations

### Key Visuals to Include:

1. **Cohort Creation Pipeline** (Slide 5)
   - Flow diagram showing data ‚Üí cohorts ‚Üí analysis

2. **Multi-Method Framework** (Slide 4)
   - Circular or flow diagram showing 5 methods

3. **FPGrowth Network Diagram** (Slide 6)
   - Network graph of frequent drug associations

4. **BupaR Process Flow** (Slide 7)
   - Sankey diagram showing drug sequences

5. **CatBoost Feature Importance** (Slide 8)
   - Horizontal bar chart of top features

6. **DTW Trajectory Clusters** (Slide 9)
   - Timeline visualization of trajectory archetypes

7. **SHAP Summary Plot** (Slide 10)
   - Beeswarm plot of feature attributions

8. **Results Summary** (Slides 11-12)
   - Multi-panel figures combining all method results

9. **Translational Pathway** (Slide 13)
   - Three-stage diagram: Data ‚Üí Analysis ‚Üí Clinical Action

---

## üìä Data to Highlight

### Quantitative Results:
- **Cohort Sizes**: Number of patients, events
- **FPGrowth**: Support/confidence metrics, number of patterns
- **CatBoost**: AUC, precision, recall, feature importance scores
- **DTW**: Silhouette scores, cluster sizes
- **SHAP**: Attribution values, causal effect sizes

### Qualitative Insights:
- **Pattern Interpretations**: What do frequent patterns mean clinically?
- **Trajectory Descriptions**: What characterizes each trajectory cluster?
- **Clinical Implications**: How can clinicians use these insights?

---

## üéØ Presentation Delivery Tips

### For Each Method Section:
1. **Problem**: What question does this method answer?
2. **Approach**: How does the method work?
3. **Results**: What did we find?
4. **Clinical Value**: Why does this matter?

### Story Arc:
1. **Setup**: The challenge (Slide 2-3)
2. **Methods**: Our approach (Slide 4-10)
3. **Results**: What we found (Slide 11-12)
4. **Translation**: Clinical applications (Slide 13-14)
5. **Impact**: Takeaways (Slide 15-17)

### Engagement Strategies:
- **Interactive Elements**: Ask audience about their experience with similar challenges
- **Case Studies**: Present specific patient trajectory examples
- **Live Demo**: Show trajectory clustering visualization (if time permits)
- **Q&A Prompts**: "What other applications can you think of?"

---

## üìù Supplementary Materials

### Handout Suggestions:
1. **Method Comparison Table**: Side-by-side comparison of all 5 methods
2. **Top Patterns List**: Top 20 drug/ICD/CPT patterns from FPGrowth
3. **Trajectory Archetypes**: Detailed descriptions of each trajectory cluster
4. **Feature Importance Rankings**: Complete rankings from CatBoost
5. **Code Repository**: Link to GitHub with analysis code

### Backup Slides:
- **Technical Details**: Deep dive into each method (if asked)
- **Additional Results**: Extended results tables
- **Validation Studies**: Cross-validation results
- **Sensitivity Analyses**: Robustness checks

---

## üéì Target Audience Considerations

### For Pharmacy Informatics Researchers:
- Emphasize methodological contributions
- Highlight multi-method integration
- Discuss computational efficiency

### For Clinical Pharmacists:
- Focus on clinical applications
- Emphasize actionable insights
- Provide practical examples

### For Healthcare Administrators:
- Highlight population health implications
- Discuss cost-effectiveness potential
- Show scalability

---

## ‚úÖ Presentation Checklist

- [ ] Prepare all visualizations (network diagrams, process flows, feature importance charts)
- [ ] Create example patient trajectories for case studies
- [ ] Prepare backup slides for technical questions
- [ ] Practice timing (45-60 minutes)
- [ ] Prepare Q&A responses for common questions
- [ ] Test all visualizations on presentation screen
- [ ] Prepare handouts/materials
- [ ] Review key messages and takeaways

---

**Presentation Version**: 1.0  
**Last Updated**: January 2025  
**Based on**: Complete analysis workflow documentation and research findings

